Czech Multicentre Research Database of Chronic Obstructive Pulmonary Disease (COPD)

NCT ID: NCT01923051

Last Updated: 2019-06-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

813 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-08-31

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The chronic obstructive pulmonary disease (COPD) is the occurrence of chronic bronchitis or emphysema, a pair of commonly co-existing diseases of the lungs in which the airways narrow over time. This limits airflow to and from the lungs, causing shortness of breath (dyspnoea). In clinical practice, COPD is defined by its characteristic airflow limitation on lung function tests. In contrast to asthma, this limitation is poorly reversible and usually gets increasingly worse over time.

The COPD registry is a non-interventional multicentre observational prospective database focusing on the collection and analysis of data on real mortality and morbidity in COPD population of the Czech Republic population of COPD patients. Monitoring is done at the occasion of regular check-ups, followed by retrospective search of data in the documentation, and a record into the registry.

The aim of Czech National Research Database of Chronic Obstructive Pulmonary Disease is to establish the clinical course of severe forms of COPD, establish the cause for deterioration of clinical status of our patients and describe the progression of COPD to death.

The registry fulfils general objectives of health registries such as monitoring of causes, development, treatment and consequences of a severe disorder, including economic and social impacts. Statistical and scientific analyses of the registry data are focused, in particular, on the assessment of health determiners of the selected patient cohort with the aim to improve health status of the patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chronic Obstructive Pulmonary Disease (COPD) is a treatable and preventable clinically heterogeneous syndrome with dominant respiratory symptoms and various systemic consequences. The incidence of COPD is increasing worldwide. In general, COPD is caused by a prolonged inflammatory reaction of a genetically predisposed individual exposed to long-term inhalation of air pollution, harmful particles and gases. This disease has a negative progression in time even after end of exposure. The pulmonary component is associated with expiratory airflow limitation, which is not fully reversible. The airflow limitation in COPD develops gradually as a result of chronic, primarily non-infectious inflammation of the airways and lung parenchyma. Systemic consequences are often found in cardiovascular, musculoskeletal and other systems. COPD can be considered a proven pre-cancerous condition.

Up-to-date and precise clinical and epidemiological data describing the situation in the Czech Republic is currently unavailable. The Czech Republic still does not have any data on representation of different phenotypes among COPD patients.

The COPD Register is a non-interventional multicenter observational prospective database focusing on the collection and analysis of data on real mortality and morbidity in an unselected (consecutive) population of patients with severe forms of COPD (post-bronchodilator FEV1≤ 60%). Monitoring is done at the occasion of regular check-ups, followed by retrospective search of data in the documentation, and a record into the registry subsequently.

The main purposes of this study:

* Assessment of all-cause mortality
* Assessment of morbidity:

(A) acute exacerbation of COPD (B) acute non-COPD respiratory events (C) acute non-respiratory events (D) cancers (E) ischemic heart disease (infarct, angina pectoris, congestive heart failure and arrhythmia)

Other aims of this study:

* Monitoring of lung function decline (post-bronchodilator FEV1)
* Monitoring of prognostic indices
* COPD categories and quality of life
* Evaluation of activity of daily living
* Assessment of therapeutic compliance

* Note: MMAS-4 questionnaire by Prof. Donald E. Morisky will not be used as of September 2018
* Analysis of extra-pulmonary impairment during

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Airway Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Post-bronchodilator FEV1/VC \< LLN and post-bronchodilator FEV1 ≤ 60% of the predicted value (VC - Vital Capacity, LLN - Lower Limit of Normal)
* Definite clinical diagnosis of COPD (can be overlaps: COPD + asthma / COPD + bronchiectasis)
* Stable course of COPD (≥ 8 weeks free of acute exacerbations and/or free of any acute conditions)
* Informed consent

Exclusion Criteria

* "Pure" bronchial asthma without COPD
* "Pure" bronchiectasis without COPD
* Cystic fibrosis
* End-stage of COPD
* Non-curable malignancy
* Total non-compliance
* Immobility
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zuzana Zbožínková, M.Sc.

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zuzana Zbožínková, M.Sc.

Zuzana Zbozinkova PharmDr

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Vladimir Koblizek, Assoc. Prof. PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Hradec Kralove

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Brno

Brno, , Czechia

Site Status

Hospital Ceske Budejovice

Ceské Budějovice, , Czechia

Site Status

University Hospital Hradec Kralove

Hradec Králové, , Czechia

Site Status

Hospital Jihlava

Jihlava, , Czechia

Site Status

Regional Hospital Liberec

Liberec, , Czechia

Site Status

Regional hospital Mlada Boleslav

Mladá Boleslav, , Czechia

Site Status

University Hospital Olomouc

Olomouc, , Czechia

Site Status

University Hospital Ostrava

Ostrava, , Czechia

Site Status

EUC Klinika Plzen

Pilsen, , Czechia

Site Status

Thomayer Hospital

Prague, , Czechia

Site Status

University Hospital in Motol

Prague, , Czechia

Site Status

Hospital Na Bulovce

Prague, , Czechia

Site Status

Masaryk Hospital in Usti nad Labem

Ústí nad Labem, , Czechia

Site Status

Tomas Bata Regional Hospital

Zlín, , Czechia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Czechia

References

Explore related publications, articles, or registry entries linked to this study.

Novotna B, Koblizek V, Zatloukal J, Plutinsky M, Hejduk K, Zbozinkova Z, Jarkovsky J, Sobotik O, Dvorak T, Safranek P. Czech multicenter research database of severe COPD. Int J Chron Obstruct Pulmon Dis. 2014 Nov 10;9:1265-74. doi: 10.2147/COPD.S71828. eCollection 2014.

Reference Type RESULT
PMID: 25419124 (View on PubMed)

Brat K, Svoboda M, Hejduk K, Plutinsky M, Zatloukal J, Volakova E, Popelkova P, Novotna B, Engova D, Franssen FME, Vanfleteren LEGW, Spruit MA, Koblizek V. Introducing a new prognostic instrument for long-term mortality prediction in COPD patients: the CADOT index. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021 Jun;165(2):139-145. doi: 10.5507/bp.2020.035. Epub 2020 Sep 10.

Reference Type DERIVED
PMID: 32955038 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://chopn.registry.cz/index-en.php

Czech National Research Database of COPD

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1301100001

Identifier Type: OTHER

Identifier Source: secondary_id

1301100001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.